BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 35830566)

  • 61. Identification of a novel autophagy signature for predicting survival in patients with lung adenocarcinoma.
    Duan J; Lei Y; Lv G; Liu Y; Zhao W; Yang Q; Su X; Song Z; Lu L; Shi Y
    PeerJ; 2021; 9():e11074. PubMed ID: 33976960
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Screening of Methylation Gene Sites as Prognostic Signature in Lung Adenocarcinoma.
    Dong M; Yang Z; Li X; Zhang Z; Yin A
    Yonsei Med J; 2020 Dec; 61(12):1013-1023. PubMed ID: 33251775
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Clinical Significance and Immunometabolism Landscapes of a Novel Recurrence-Associated Lipid Metabolism Signature In Early-Stage Lung Adenocarcinoma: A Comprehensive Analysis.
    Zhu M; Zeng Q; Fan T; Lei Y; Wang F; Zheng S; Wang X; Zeng H; Tan F; Sun N; Xue Q; He J
    Front Immunol; 2022; 13():783495. PubMed ID: 35222371
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Construction of a Redox-Related Prognostic Model with Predictive Value in Survival and Therapeutic Response for Patients with Lung Adenocarcinoma.
    Xiao L; Li Q; Huang Y; Fan Z; Ma L; Liu B; Yuan X
    J Healthc Eng; 2022; 2022():7651758. PubMed ID: 35251577
    [TBL] [Abstract][Full Text] [Related]  

  • 65. A large cohort study identifying a novel prognosis prediction model for lung adenocarcinoma through machine learning strategies.
    Li Y; Ge D; Gu J; Xu F; Zhu Q; Lu C
    BMC Cancer; 2019 Sep; 19(1):886. PubMed ID: 31488089
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Identification and Validation of a Novel Signature Based on NK Cell Marker Genes to Predict Prognosis and Immunotherapy Response in Lung Adenocarcinoma by Integrated Analysis of Single-Cell and Bulk RNA-Sequencing.
    Song P; Li W; Guo L; Ying J; Gao S; He J
    Front Immunol; 2022; 13():850745. PubMed ID: 35757748
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Immunoprognostic model of lung adenocarcinoma and screening of sensitive drugs.
    Liang P; Li J; Chen J; Lu J; Hao Z; Shi J; Chang Q; Zeng Z
    Sci Rep; 2022 May; 12(1):7162. PubMed ID: 35504892
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Comprehensive Analysis of a Nine-Gene Signature Related to Tumor Microenvironment in Lung Adenocarcinoma.
    Zhong H; Wang J; Zhu Y; Shen Y
    Front Cell Dev Biol; 2021; 9():700607. PubMed ID: 34540825
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Identification of a Seven-lncRNA Immune Risk Signature and Construction of a Predictive Nomogram for Lung Adenocarcinoma.
    Jin D; Song Y; Chen Y; Zhang P
    Biomed Res Int; 2020; 2020():7929132. PubMed ID: 32596372
    [TBL] [Abstract][Full Text] [Related]  

  • 70. A gene expression-based immune signature for lung adenocarcinoma prognosis.
    Wang L; Luo X; Cheng C; Amos CI; Cai G; Xiao F
    Cancer Immunol Immunother; 2020 Sep; 69(9):1881-1890. PubMed ID: 32372138
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Analysis of prognostic model based on immunotherapy related genes in lung adenocarcinoma.
    Zhang P; Wang W; Liu L; Li H; Sha X; Wang S; Huang Z; Zhou Y; Shi J
    Sci Rep; 2022 Dec; 12(1):22077. PubMed ID: 36543847
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Analysis of genomic and transcriptomic variations as prognostic signature for lung adenocarcinoma.
    Zengin T; Önal-Süzek T
    BMC Bioinformatics; 2020 Sep; 21(Suppl 14):368. PubMed ID: 32998690
    [TBL] [Abstract][Full Text] [Related]  

  • 73. The Comprehensive Analysis Identified an Autophagy Signature for the Prognosis and the Immunotherapy Efficiency Prediction in Lung Adenocarcinoma.
    Li X; Dai Z; Wu X; Zhang N; Zhang H; Wang Z; Zhang X; Liang X; Luo P; Zhang J; Liu Z; Zhou Y; Cheng Q; Chang R
    Front Immunol; 2022; 13():749241. PubMed ID: 35529878
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Identification of an immune-related six-long noncoding RNA signature as a novel prognosis biomarker for adenocarcinoma of lung.
    Miao H; Chen D; Li R; Hu J; Chen Y; Xu C; Wen Z
    Biosci Rep; 2021 Jan; 41(1):. PubMed ID: 33324975
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Tumor microenvironment related novel signature predict lung adenocarcinoma survival.
    Chen J; Zhou R
    PeerJ; 2021; 9():e10628. PubMed ID: 33520448
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Abnormal Expression and Prognostic Significance of Bone Morphogenetic Proteins and Their Receptors in Lung Adenocarcinoma.
    Xu Z; Chen C
    Biomed Res Int; 2021; 2021():6663990. PubMed ID: 34036102
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Identification of Prognostic Signature and Gliclazide as Candidate Drugs in Lung Adenocarcinoma.
    Cheng Y; Hou K; Wang Y; Chen Y; Zheng X; Qi J; Yang B; Tang S; Han X; Shi D; Wang X; Liu Y; Hu X; Che X
    Front Oncol; 2021; 11():665276. PubMed ID: 34249701
    [TBL] [Abstract][Full Text] [Related]  

  • 78. CD8
    Zhang M; Ma J; Guo Q; Ding S; Wang Y; Pu H
    Front Immunol; 2022; 13():806877. PubMed ID: 35273597
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Prognostic value and immune infiltration of a novel stromal/immune score-related P2RY12 in lung adenocarcinoma microenvironment.
    Yu L; Cao S; Li J; Han B; Zhong H; Zhong R
    Int Immunopharmacol; 2021 Sep; 98():107734. PubMed ID: 34175738
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Analysis of prognostic genes in the tumor microenvironment of lung adenocarcinoma.
    Xu ZY; Zhao M; Chen W; Li K; Qin F; Xiang WW; Sun Y; Wei J; Yuan LQ; Li SK; Lin SH
    PeerJ; 2020; 8():e9530. PubMed ID: 32775050
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.